Investors poured almost $23 billion into rare disease therapeutics development last year, a 28% increase over 2020. Patients have been the spark plug behind the robust funding for, and greater attention around, these drugs. Craig Martin, CEO of rare disease advocacy group Global Genes, explains the perils and pitfalls to this patient-led revolution.